ADCT vs. MRSN, NKTR, CCCC, CTMX, VERV, MIRM, PRTA, COLL, ELVN, and SAVA
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Mersana Therapeutics (MRSN), Nektar Therapeutics (NKTR), C4 Therapeutics (CCCC), CytomX Therapeutics (CTMX), Verve Therapeutics (VERV), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), and Cassava Sciences (SAVA). These companies are all part of the "medical" sector.
Mersana Therapeutics (NASDAQ:MRSN) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.
Mersana Therapeutics currently has a consensus target price of $6.29, indicating a potential upside of 169.77%. ADC Therapeutics has a consensus target price of $7.25, indicating a potential upside of 111.37%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Mersana Therapeutics is more favorable than ADC Therapeutics.
Mersana Therapeutics received 194 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 65.78% of users gave Mersana Therapeutics an outperform vote while only 65.00% of users gave ADC Therapeutics an outperform vote.
Mersana Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 11.8% of Mersana Therapeutics shares are held by insiders. Comparatively, 4.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, ADC Therapeutics had 4 more articles in the media than Mersana Therapeutics. MarketBeat recorded 7 mentions for ADC Therapeutics and 3 mentions for Mersana Therapeutics. ADC Therapeutics' average media sentiment score of 1.22 beat Mersana Therapeutics' score of 0.13 indicating that Mersana Therapeutics is being referred to more favorably in the media.
ADC Therapeutics has a net margin of -330.17% compared to ADC Therapeutics' net margin of -352.01%. ADC Therapeutics' return on equity of -260.65% beat Mersana Therapeutics' return on equity.
Mersana Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
Summary
Mersana Therapeutics beats ADC Therapeutics on 13 of the 18 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
